Tempus AI, Inc. (TEM)
| Market Cap | 14.47B -7.3% |
| Revenue (ttm) | 1.51B +36.6% |
| Net Income | -189.29M |
| EPS | -1.05 |
| Shares Out | 182.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,622,605 |
| Open | 80.75 |
| Previous Close | 78.48 |
| Day's Range | 78.87 - 84.47 |
| 52-Week Range | 40.77 - 90.53 |
| Beta | 3.54 |
| Analysts | Buy |
| Price Target | 82.50 (+3.77%) |
| Earnings Date | Nov 2, 2026 |
About TEM
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $82.5, which is an increase of 3.77% from the latest price.
News
Tempus AI price target raised to $120 from $100 at Mizuho
Mizuho analyst Bradley Bowers raised the firm’s price target on Tempus AI (TEM) to $120 from $100 and keeps an Outperform rating on the shares. The firm says the company’s…
Tempus AI price target raised to $92 from $80 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Tempus AI (TEM) to $92 from $80 and keeps an Overweight rating on the shares. Tempus AI’s Q3 results reinforced accelerating growth…
Tempus AI price target raised to $100 from $80 at BTIG
BTIG raised the firm’s price target on Tempus AI (TEM) to $100 from $80 and keeps a Buy rating on the shares after its Q3 earnings beat and guidance raise.
Tempus AI price target raised to $89 from $73 at Freedom Capital
Freedom Capital raised the firm’s price target on Tempus AI (TEM) to $89 from $73 and keeps a Hold rating on the shares. The firm is “incrementally more positive” on…
Tempus AI price target raised to $92 from $85 at Baird
Baird raised the firm’s price target on Tempus AI (TEM) to $92 from $85 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
Tempus AI price target raised to $85 from $68 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Tempus AI (TEM) to $85 from $68 and keeps a Buy rating on the shares. The firm increased the stock’s multiple following…
Tempus AI upgraded to Hold from Underperform at Jefferies
Jefferies upgraded Tempus AI (TEM) to Hold from Underperform with a price target of $70, up from $35. The firm is citing the company’s solid Q3 earnings beat and narrowing…
Tempus AI upgraded to Hold from Underperform at Jefferies
Jefferies analyst Tycho Peterson upgraded Tempus AI (TEM) to Hold from Underperform with a price target of $70, up from $35.
Tempus AI Earnings Call Transcript: Q3 2026
Q3 revenue rose 23% YoY to $411.5M, with growth in diagnostics and data/apps; Adjusted EBITDA was $25.6M. 2026 revenue guidance increased to $1.60B–$1.605B, while Adjusted EBITDA guidance remained approximately $65M.
Tempus AI Slides: Q3 2026
Tempus AI has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Tempus AI Earnings release: Q3 2026
Tempus AI released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Tempus AI Quarterly report: Q3 2026
Tempus AI has published its Q3 2026 quarterly earnings report on November 2, 2026.
Tempus AI Prepared remarks: Q3 2026
Tempus AI filed a regulatory document on November 2, 2026 disclosing important business information.
Tempus AI's Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer
Tempus AI reported better-than-expected third-quarter earnings Monday as demand for its cancer-testing services surged.
Tempus AI reports Q3 EPS 7c, consensus (8c)
Reports Q3 revenue $411.5M, consensus $409.3M. “Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and…
Tempus AI sees FY26 revenue $1.6B-$1.605B, consensus $1.6B
Tempus is increasing its full year 2026 revenue guidance to $1.6B-$1.605B, which represents ~25% annual growth. The company continues to expect 2026 Adjusted EBITDA to be $65M. Published first on…
Tempus Reports Third Quarter 2026 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September...
Tempus AI receives IVDR certification for xR RNA sequencing
Tempus AI (TEM) announced that its xR assay has received certification under the European Union’s In Vitro Diagnostic Regulation, IVDR, as a Class C in vitro diagnostic device. The certification…
Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union's In Vitro Diagnostic Regulation (IVDR) as a Class C in vi...
Tempus AI price target raised to $68 from $66 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Tempus AI (TEM) to $68 from $66 and keeps a Buy rating on the shares after the company announced an expanded collaboration…
Pathos AI enters collaborations with Bristol Myers, Tempus AI
Pathos AI announced multi-year strategic collaborations with Bristol Myers Squibb (BMY) and Tempus AI (TEM) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease ...
Tempus AI expands collaboration with Bristol Myers
Tempus AI (TEM) announced a multi-year agreement with Bristol Myers Squibb (BMY), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insi...
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology ...
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions
NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (...
How Tempus AI Built a Defensible Data Moat in Precision Healthcare
As access to powerful general-purpose AI models expands, access alone offers limited differentiation. In precision healthcare, competitive advantage can come from combining proprietary clinical data, ...